The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir

AIDS

Volumn 12, Issue 5, 1998, Pages

  Kempf, Dale J ^a   Rode, Richard A ^a   Xu, Yi ^a   Sun, Eugene ^a   Heath Chiozzi, Margo E ^a   Valdes, Joaquin ^a   Japour, Anthony J ^a   Danner, Sven ^b   Boucher, Charles ^c   Molla, Akhteruzzaman ^a   Leonard, John M ^a  

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Durability of response; Protease inhibitor; Resistance; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; ASSAY; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 15144357022     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199805000-00001     Document Type: Article

References (19)

1. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
2. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
3. Cohen C, Sun E, Cameron W, et al.: Ritonavir-saquinavir combination treatment in HIV-infected patients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 1996 [abstract 1.B7b].
4. Sarcletti M, Petter A, Steinhuber S, Fuchs D, Most J, Zangerle R: Efficacy of triple therapy in pretreated patients in a specialized routine clinical setting. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 237].
5. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
6. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
7. Kohl NE, Emini EA, Schleif WA, et al.: Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988, 85:4686-4690.
8. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
9. O'Brien WA, Hartigan PM, Martin D, et al.: Changes in plasma HIV-RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426-431.
10. Heath-Chiozzi M, Leonard J, Sun E, et al.: Ritonavir clinical benefit correlates with HIV RNA and CD4 cell levels in advanced HIV illness. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeB3127].
11. Saag MS, Holodniy M, Kuritzkes DR, et al.: HIV viral load markers in clinical practice. Nature Med 1996, 2:625-629.
12. Kempf D, Marsh KC, Denissen JF, et al.: ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995, 92:2484-2488.
13. Danner SA, Carr A, Leonard JM, et al.: A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528-1533.
14. Schuurman R, Descamps D, Weverling GJ, et al.: Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1996, 34:3016-3122.
15. Welles S, Jackson J, Yen-Lieberman B, et al.: Prognostic value of plasma HIV-1 RNA levels in patients with advanced HIV-1 disease and with little or no zidovudine therapy. J Infect Dis 1996, 174:696-703.
16. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1996, 271:1582-1586.
17. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
18. Patick AK, Duran M, Cao Y, et al.: Genotypic analysis of HIV-1 variants isolated from patients treated with the protease inhibitor nelfinavir, alone or in combination with d4T or AZT and 3TC. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 10].
19. Schapiro JM, Winters MA, Vierra M, Jacobsen H, Mous J, Merigan TC: Resistance mutations in patients receiving saquinavir: simultaneous appearance in lymph nodes, peripheral blood mononuclears (PBM) and plasma. Fifth International Workshop of HIV Drug Resistance. Whistler, July 1996 [abstract 28].